Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Liabilities from Discontinued Operations (2018 - 2023)

Aclaris Therapeutics has reported Liabilities from Discontinued Operations over the past 6 years, most recently at 2202000.0 for Q4 2023.

  • Quarterly results put Liabilities from Discontinued Operations at 2202000.0 for Q4 2023, changed 0.0% from a year ago — trailing twelve months through Dec 2023 was 2202000.0 (changed 0.0% YoY), and the annual figure for FY2023 was 2202000.0, changed 0.0%.
  • Liabilities from Discontinued Operations for Q4 2023 was 2202000.0 at Aclaris Therapeutics, roughly flat from 2202000.0 in the prior quarter.
  • Over the last five years, Liabilities from Discontinued Operations for ACRS hit a ceiling of 14501000.0 in Q3 2019 and a floor of 2198000.0 in Q3 2021.
  • Median Liabilities from Discontinued Operations over the past 5 years was 2202000.0 (2021), compared with a mean of 3228666.67.
  • Biggest five-year swings in Liabilities from Discontinued Operations: skyrocketed 238.79% in 2019 and later plummeted 77.24% in 2020.
  • Aclaris Therapeutics' Liabilities from Discontinued Operations stood at 4157000.0 in 2019, then decreased by 25.16% to 3111000.0 in 2020, then fell by 29.22% to 2202000.0 in 2021, then changed by 0.0% to 2202000.0 in 2022, then changed by 0.0% to 2202000.0 in 2023.
  • The last three reported values for Liabilities from Discontinued Operations were 2202000.0 (Q4 2023), 2202000.0 (Q3 2023), and 2202000.0 (Q2 2023) per Business Quant data.